Shares of Eli Lilly & Co. LLY slipped 6.59% to $744.91 Tuesday, on what proved to be an all-around great trading session for ...

Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential ...

Palantir stock rebounds, sales of Eli Lilly’s blockbuster GLP-1 medicines miss estimates, and Boeing’s 2024 deliveries fall ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s disease, an inflammatory bowel disease that causes chronic abdominal pain.

Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is ...

Eli Lilly's outlook for sales of its blockbuster ... following the December report on producer prices. The Dow Jones Industrial Average, S&P 500, and Nasdaq all were down less than 0.5%.

For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast ...

Wall Street analyzed the cooler-than-expected producer price index for December on Tuesday and looked ahead to the consumer ...

while Dow Jones Industrial Average futures fell 0.2% and S&P 500 futures were 0.1% lower. All three major indexes rose Tuesday, helped by strong corporate earnings from Palantir, Eli Lilly ...

though drops for Eli Lilly and other influential stocks kept indexes in check. The S&P 500 rose 0.1% as three out of every four stocks in the index climbed. The Dow Jones Industrial Average added ...